Overview

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.

Phase:

Phase 2

Details

Lead Sponsor:

Aarti Bhatia
Yale University

Collaborators:

Boehringer Ingelheim
National Comprehensive Cancer Network

Treatments:

Afatinib
Cetuximab